{"organizations": [], "uuid": "dd7696ad8b8bc836c99b750ed505d8c2c7eded80", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.freshnews.com", "main_image": "", "site_section": "http://freshnews.com//news/technology/feed", "section_title": "FreshNews.com - Technology News", "url": "http://www.freshnews.com/news/1125152/walvax-biotechnology-selects-medidata-s-cloud-based-platform-advance-pediatric-vaccine", "country": "US", "title": "Walvax Biotechnology Selects Medidata’s Cloud-Based Platform to Advance Pediatric Vaccine Program in China", "performance_score": 0, "site": "freshnews.com", "participants_count": 1, "title_full": "Walvax Biotechnology Selects Medidata’s Cloud-Based Platform to Advance Pediatric Vaccine Program in China", "spam_score": 0.0, "site_type": "news", "published": "2015-09-09T00:30:00.000+03:00", "replies_count": 0, "uuid": "dd7696ad8b8bc836c99b750ed505d8c2c7eded80"}, "author": "admin", "url": "http://www.freshnews.com/news/1125152/walvax-biotechnology-selects-medidata-s-cloud-based-platform-advance-pediatric-vaccine", "ord_in_thread": 0, "title": "Walvax Biotechnology Selects Medidata’s Cloud-Based Platform to Advance Pediatric Vaccine Program in China", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Submitted by admin on 9/8/2015 @ 2:30 PM   Medidata \nNEW YORK -- (BUSINESS WIRE) -- Medidata (NASDAQ: MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced that its industry-leading technology platform has been adopted by Walvax Biotechnology Co. , Ltd (“Walvax”) (SZSE: 300142), a biopharmaceutical company in China. Walvax is harnessing the Medidata Clinical Cloud ® platform to improve data management activities and drive biomedical innovation in the development of a pneumococcal conjugate vaccine for infants. \n“Pneumococcal infections—including pneumonia, blood infections and meningitis—can be extremely difficult to treat, making prevention through vaccination a critical component of patient care,” said Yi Zhang, Vice President, Walvax. “We’re pleased to be using Medidata’s robust, globally-validated technology to bring greater speed and operational efficiencies to our pneumococcal conjugate vaccine trials, ultimately leading to a safe and effective way to ensure young children are protected from the devastating effects of pneumococcal diseases.” \nFounded in 2001, Walvax Biotechnology specializes in the research, development, production and distribution of bio-medicine products, including vaccines and blood products. To optimize the execution of its novel research on a vaccine for pneumococcal conjugate (PCV13)—the first multi-center clinical trials to be conducted on infants and toddlers in China—Walvax is utilizing Medidata’s cloud-based technology for electronic data capture and management ( Medidata Rave ® ). The Chinese biopharmaceutical company is also leveraging training available through Medidata’s professional services offering to speed study implementation and ensure trial timelines are met. \n\"Medidata's cloud-based platform is designed to bring efficiencies to clinical trials of all sizes and therapeutics areas,\" said Takeru Yamamoto, Medidata’s managing director of the Asia-Pacific (APAC) region. \"We’re proud to be collaborating with Walvax as the organization advances pneumococcal conjugate vaccine research in China, resulting in better preventative treatment for young people around the world.\" \nAbout Walvax Biotechnology \nWalvax Biotechnology Co., Ltd. (“Walvax”) was founded in 2001, which is a modern biological pharmaceutical enterprise engaged in R & D, production and sales of bio-medicine products. Walvax is a National Validated High-tech Enterprise and Enterprise Technical Center. In November, 2010, Walvax Biotechnology Co., Ltd. (stock name: Walvax Biotech, and stock code: 300142) listed on Shenzhen Stock Exchange. Walvax is committed to provide safe bio-medicine (such as vaccines, blood products and so on) with excellent quality and advanced technology for domestic and foreign markets. \nWalvax’s headquarters is located in Kunming, Yunnan Province of China. Walvax has a staff of more than 1,200, and has a modern R&D center in National High-tech Zone of Kunming, and a modern vaccine production base and pilot base in High-tech Zone of Yunnan Yuxi and Jiangsu Taizhou China Medical City, respectively. Walvax’s marketing network covers 30 provinces and cities of China, which includes more than 2,000 counties. \nAbout Medidata \nMedidata is the leading global provider of cloud-based solutions for clinical research in life sciences, transforming clinical development through its advanced applications and intelligent data analytics. The Medidata Clinical Cloud ® brings new levels of productivity and quality to the clinical testing of promising medical treatments, from study design and planning through execution, management and reporting. We are committed to advancing the competitive and scientific goals of global customers, which include over 90% of the top 25 global pharmaceutical companies; innovative biotech, diagnostic and device firms; leading academic medical centers; and contract research organizations. View source version on businesswire.com: http://www.businesswire.com/news/home/20150908006716/en/ Copyright © Business Wire 2015", "external_links": [], "published": "2015-09-09T00:30:00.000+03:00", "crawled": "2015-09-09T01:39:40.697+03:00", "highlightTitle": ""}